Sign inCreate account

Report workspace tools

NCT03709823COMPLETEDanonymous

A Multicenter, Double-blind, Randomized, Placebo-controlled Phase 2b Trial of Cytisine in Adult Smokers

Sponsor

Source record

Achieve Life Sciences

Phase

Source record

PHASE2

Modality

AI-normalized

small molecule

Target

AI-normalized

Cytisine, Placebo Comparator, Behavioral support

Indication / condition

AI-normalized

Smoking Cessation

Intervention

Source record

Cytisine, Placebo Comparator, Behavioral support

Source & freshness

Source record

NCT ID

NCT03709823

Original source

ClinicalTrials.gov

Source last updated

May 18, 2020

Ingested at

Jun 08, 2026

Internal sync

Jun 08, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT03709823

Title

A Multicenter, Double-blind, Randomized, Placebo-controlled Phase 2b Trial of Cytisine in Adult Smokers

Sponsor

Achieve Life Sciences

Status

COMPLETED

Phase

PHASE2

Condition raw

Smoking Cessation

Condition normalized

Smoking Cessation

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Cytisine, Placebo Comparator, Behavioral support

Target normalized

Cytisine, Placebo Comparator, Behavioral support

Interventions

Cytisine, Placebo Comparator, Behavioral support

Public preview

Source record

This placebo-controlled Phase 2b trial is being conducted at sites within the United States (US) to evaluate the effectiveness cytisine dosage (1.5 mg, 3.0 mg) and administration schedule (commercial titration versus simplified 3 times daily \[TID\] schedule) within a 25-day treatment period.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Multicenter, Double-blind, Randomized, Placebo-controlled Phase 2b Trial of Cytisine in Adult Smokers

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT03709823

Status

COMPLETED

Phase

PHASE2

Sponsor

Achieve Life Sciences

Executive brief

Investment-Ready Snapshot

This placebo-controlled Phase 2b trial is being conducted at sites within the United States (US) to evaluate the effectiveness cytisine dosage (1.5 mg, 3.0 mg) and administration schedule (commercial titration versus simplified 3 times daily \[TID\] schedule) within a 25-day treatment period.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMay 18, 2020
Internal syncJun 08, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03709823

Indication

Smoking Cessation

Modality

small molecule

Target

Cytisine, Placebo Comparator, Behavioral support

Intervention

Cytisine, Placebo Comparator, Behavioral support

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.